Organisational barriers to thrombolysis treatment of acute ischaemic stroke

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2833-2839

  Ehlers, Lars ^a   Jensen, Lotte Groth ^a   Bech, Merete ^a   Andersen, Grethe ^a   Kjølby, Mette ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute care; Economics; Health policy; Organisation; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT;

CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DATA BASE; DENMARK; FIBRINOLYTIC THERAPY; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; REVIEW;

BRAIN ISCHEMIA; DENMARK; FIBRINOLYTIC AGENTS; HUMANS; STROKE;

EID: 36348961292     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242557     Document Type: Review

References (27)

1. Martin J. Meltzer H, Elliot D. OPCS surveys of disability in Great Britain Report 1: The prevalence of disability among adults. London: Office of Population Censuses and Surveys, HMSO, 1998
2. Hacke W, Donnan G, Fieschi C, Kaste M, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74
3. Fagan SC, Morgenstern LB, Petitta A, et al. and the NINDS rt-PA Stroke Study Group. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998;50:883-90
4. Sinclair S, Frighetto L, Loewen P, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 2001;19:927-36
5. Sandercock P, Berge E, Dennis M, et al. A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health Technol Assess 2002;6:1-112
6. Ehlers L, Andersen G, Clausen LB, et al. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 2007;38:85-9
7. Danish Secretariat for Clinical Guidelines (DSCG). Guideline recommendations: Clinical Guideline for the Treatment of Patients with Stroke. Copenhagen: National Board of Health; 2005
8. Bech M, Ehlers L, Andersen G, et al. HTA of thrombolytic therapy in patients with acute ischemic stroke. Aarhus: HTA Unit, Aarhus University Hospital, Department of Public Health, The County of Aarhus, Denmark; 2005. (only in Danish)
9. Danish Neurological Society (Working group). Consensus report on setting-up thrombolysis centres for treatment of acute ischemic stroke (draft) [in Danish]. Copenhagen: Danish Neurological Society, 2004
10. National Board of Health. Letter of 5 March 2004. Thrombolytic treatment of acute ischemic stroke [in Danish]. Copenhagen: Advisory Unit for Planning of Specialised Functions, 2004
11. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 2005;36:2500-3
12. Safe Implementation of Thrombolysis in Stroke. Available at www.acutestroke.org [Last accessed 21 January 2007]
13. DACEHTA. Available at www.cemtv.dk [Last accessed 3 July 2007]
14. EUNETHTA. Available at www.eunetha.net [Last accessed 3 July 2007]
15. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-82
16. US Census Bureau. Available at www.census.gov [Last accessed 21 January 2007]
17. Lindley IR. Thrombolysis for acute stroke in the United Kingdom. Age Ageing 2002;31:28-30
18. Innes K, IST-3 Stroke Nurse Group. Thrombolysis for acute ischaemic stroke: core nursing requirements. Br J Nurs 2003;12:416-24
19. Kwan J, Hand P, Sandercock P. Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review, Q J Med 2004; 97,273-9
20. Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing 2004;33:116-21
21. Núnez A C G. Mora J V. Organization of medical care in acute stroke: importance of a good network. Cerebrovasc Dis 2004;17(Suppl 1):113-23
22. Walters MR, Muir KW, Harbison KRl, Ford GA. Intravenous thrombolysis for acute ischaemic stroke: preliminary experience with recombinant tissue plasminogen activator in the UK. Cerebrovasc Dis 2005;20,438-42
23. Audebert HJ, Kukla C, von Claranau SC, et al. Telemedicine for safe and extended use of thrombolysis in stroke. The telemedic pilot project for integrative stroke care (TEMPis) in Bavaria. Stroke 2005;36,287-91
24. Audebert HJ, Kukla C, von Claranau SC, et al. Comparison of tissue plasminogen activator administration management between telestroke network hospitals and academic stroke centers. Stroke 2006;37:1822-7
25. Carty R, Mooraby R, Paterson J. Evolution of a model for the thrombolysis of acute stroke patients. Br J Nurs 2006;15:453-7
26. Patel A, Knapp M, Perez I, et al. Alternative strategies for stroke care. Stroke 2004;35:196-204
27. EMEA. Committee for Proprietary Medicinal Products (CPMP). Summary information on a referral opinion following an arbitration, pursuant to article 29 of directive 2001/83/ec, for Actilyse. London: The European Agency for the Evaluation of Medicinal Products, 21 November 2002